Our findings may facilitate therapeutic strategies targeting the most dangerous CLL cell fractions and provide a strong rationale for the use of monoclonal antibodies for CCR7 and CXCR4 that are currently being trialed.50, 51. Here, CCR7 is linked to B-cell chronic lymphocytic leukemia.